Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
For overlap across multiple ETFs use Portfolio Builder
11
Number of overlapping holdings
18.3%
% of XLV's 60 holdings also in MEDX
36.7%
% of MEDX's 30 holdings also in XLV
Overlap by Weight
Sector Drift (XLV minus MEDX)
Overlapping Holdings
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in XLV |
Weight in MEDX |
Overlap | |
|---|---|---|---|---|
 |
ELI LILLY & CO | 12.3% | 16.8% | 12.3% |
|
ABBVIE INC | 6.9% | 9.6% | 6.9% |
|
JOHNSON & JOHNSON | 7.5% | 5.1% | 5.1% |
|
MERCK & CO. INC. | 4.3% | 3.6% | 3.6% |
|
AMGEN INC | 3.1% | 6.3% | 3.1% |
Position Highlights (Non-Overlapping Exposures)
XLV Overweight Relative to MEDX
|
UNITEDHEALTH GROUP INC | 9.0% |
|
ABBOTT LABORATORIES | 4.3% |
|
THERMO FISHER SCIENTIFIC INC | 3.6% |
|
INTUITIVE SURGICAL INC | 3.3% |
|
BOSTON SCIENTIFIC CORP | 2.8% |
|
GILEAD SCIENCES INC | 2.6% |
|
DANAHER CORP | 2.5% |
|
VERTEX PHARMACEUTICALS INC | 2.4% |
|
JOHNSON & JOHNSON | 2.4% |
|
STRYKER CORP | 2.4% |
XLV Underweight Relative to MEDX
 |
NOVARTIS AG-ADR | -6.6% |
 |
ASTRAZENECA PLC-SPONS ADR | -5.6% |
|
ALNYLAM PHARMACEUTICALS INC | -4.7% |
 |
ALKERMES PLC | -4.7% |
|
ELI LILLY & CO | -4.5% |
|
BRISTOL-MYERS SQUIBB CO | -4.2% |
|
AMGEN INC | -3.1% |
|
ABBVIE INC | -2.7% |
|
GLAXOSMITHKLINE PLC-SPON ADR | -2.7% |
|
CRISPR THERAPEUTICS AG | -2.4% |